A Phase 1/2 Feasibility, Safety, and Activity Study of PSCA-Specific Chimeric Antigen Receptor Engineered T Cells (BPX-601) in Subjects with Previously Treated Advanced Solid Tumors
Clinical Trial Grant
Awarded By
Bellicum Pharmaceuticals, Inc.
Start Date
July 14, 2022
End Date
July 14, 2022
Awarded By
Bellicum Pharmaceuticals, Inc.
Start Date
July 14, 2022
End Date
July 14, 2022